Tiziana Life Sciences Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Gabriele Marco Cerrone

Chief Executive Officer (CEO)

US$817.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	10.6yrs
Participación del CEO	38.4%
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Oct 12

Tiziana chief medical officer further increases holdings in company

Sep 23

Tiziana Life Sciences executive chairman further raises stake in company

Sep 16

Tiziana executive chairman raises stake in company again, buys more shares

Aug 25

Tiziana Life Sciences discloses share purchase by executive chairman

Aug 17

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Aug 15

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Jul 15

CEO

Gabriele Marco Cerrone (52 yo)

10.6yrs

Permanencia

US$817,000

Compensación

Mr. Gabriele Marco Antonio Cerrone, MBA, is the Founder of Tiziana Life Sciences Ltd and has been its Executive Chairman and Director since April 24, 2014 and serves as its Interim Chief Executive Officer....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gabriele Marco Cerrone	Founder	no data	US$817.00k	38.39% $ 38.2m
Keeren Shah	COO & CFO	less than a year	sin datos	sin datos
William Clementi	Chief Development Officer	1.2yrs	sin datos	sin datos
Napoleone Ferrara	Member of Scientific Advisory Board	10.5yrs	sin datos	sin datos

1.2yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TLSA no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gabriele Marco Cerrone	Founder	10.6yrs	US$817.00k	38.39% $ 38.2m
Napoleone Ferrara	Member of Scientific Advisory Board	no data	sin datos	sin datos
John Brancaccio	Independent Non-Executive Director	4.3yrs	US$89.00k	sin datos
Howard L. Weiner	Chairman of Scientific Advisory Board	8.8yrs	sin datos	sin datos
Willy Simon	Independent Non-Executive Director	9yrs	US$89.00k	0.0080% $ 8.0k
Arun Sanyal	Member of Scientific Advisory Board	7.7yrs	sin datos	sin datos
Kevan Herold	Member of Scientific Advisory Board	8.8yrs	sin datos	sin datos

8.8yrs

Permanencia media

73yo

Promedio de edad

Junta con experiencia: La junta directiva de TLSA se considera experimentada (8.8 años de antigüedad promedio).

Tiziana Life Sciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Insufficient new directors

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023

Insufficient new directors

Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer

Recent updates

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Tiziana Life Sciences Ltd has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Insufficient new directors

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program

Tiziana Life Sciences Ltd announced delayed 20-F filing

Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology

New minor risk - Share price stability

Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis

New minor risk - Financial data availability

Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment

Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)

Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023

New major risk - Share price stability

Insufficient new directors

Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Reduction in Microglial Activation in Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces IND Filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer

Tiziana Life Sciences Ltd Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (Spms) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Completion of Prerequisite Pre-Clinical Safety Study

Tiziana Life Sciences Ltd. Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirements

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 29, 2022

Tiziana Life Sciences Ltd Announces Publication of A Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T Cell Function and an Induced T Cell Regulatory Response in Human Subjects

Less than half of directors are independent

Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (Cns)

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for Its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in Its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Ltd. Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Tiziana chief medical officer further increases holdings in company

Tiziana Life Sciences Ltd Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (Spms) After Six Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd(NasdaqGM:TLSA) dropped from S&P Global BMI Index

Tiziana Life Sciences Announces Grant Received by the Brigham and Women’S Hospital to Explore the Use of Intranasal Anti-Cd3 Mab in Amyotrophic Lateral Sclerosis

Tiziana Life Sciences executive chairman further raises stake in company

Tiziana executive chairman raises stake in company again, buys more shares

Tiziana Life Sciences discloses share purchase by executive chairman

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Tiziana Life Sciences Appoints Matthew W. Davis as Chief Medical Officer and Acting Chief Scientific Officer

Tiziana Life Sciences Ltd Announces Resignation of Kunwar Shailubhai as Chief Scientific Officer and Board Director

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Tiziana Life Sciences Receives Nasdaq Deficiency Notice

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Less than half of directors are independent

Tiziana Life Sciences Announces FDA Grants Permission to Enroll Up to 8 Additional Secondary Progressive Multiple Sclerosis Patients in the Expanded Access Program with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, Fully Human Anti-Cd3 Monoclonal Antibody, in Patients with Crohn’s Disease

Tiziana Life Sciences PLC (NasdaqGM:TLSA) announces an Equity Buyback for $5 million worth of its shares.

Tiziana Life Sciences PLC Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

Less than half of directors are independent

CEO

Permanencia